Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry · 2026
DOI: 10.1080/14756366.2025.2609342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2026. Verfasst von Mohammad Hassan Baig und 8 weiteren Autor:innen. Beteiligte Einrichtung: BNJBiopharma, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Drug Design, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Start-up Growth Technology Development Program, Industrial Technology International Cooperation Program, Start-up Leap Package Program.
Abstract (Originalsprache)
KRAS-G12D mutations are common drivers of pancreatic and colorectal cancers, yet effective targeted therapies remain limited. This study describes the design, synthesis, and biological evaluation of two novel KRAS-G12D inhibitors, GD-2 and GD-4. Both compounds exhibited strong antiproliferative activity in AGS and ASPC1 cancer cell lines, with IC₅。 values ranging from 0.2 to 1.8 µM. The protein binding assay also demonstrated high affinity for KRAS-G12D, with dissociation constants (Kd) of 146 nM for GD-2 and 3.18 nM for GD-4. Mechanistic investigations revealed that both compounds significantly reduced downstream, as evidenced by a clear decrease in phospho-ERK expression. Additionally, molecular dynamics simulations confirmed stable binding interactions within the KRAS-G12D pocket. Collectively, these findings identify GD-2 and GD-4 as promising therapeutic candidates for KRAS-G12D-driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BNJBiopharma, Incheon, Republic of Korea.
- HANDOK Inc, Seoul, Republic of Korea.
- Graduate School of Future Strategy, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Department of Family Medicine, Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Republic of Korea.
Förderung
- Start-up Growth Technology Development Program
- Industrial Technology International Cooperation Program
- Start-up Leap Package Program
Zitieren
APA
Baig, M. H., Jo, Y. S., Nale, S. D., Kim, C. J., Park, J., Ha, J., Moon, B., Ryu, S., & Dong, J. J. (2026). Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2025.2609342
Vancouver
Baig MH, Jo YS, Nale SD, Kim CJ, Park J, Ha J, et al. Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026. doi:10.1080/14756366.2025.2609342
BibTeX
@article{Baig2026,
author = {Baig, Mohammad Hassan and Jo, Yun Seong and Nale, Sagar Dattatraya and Kim, Chang Joong and Park, JiMin and Ha, JaIn and Moon, ByoungGon and Ryu, Sungwook and Dong, Jae-June},
title = {Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2026},
doi = {10.1080/14756366.2025.2609342}
}
EUVIMED